We partner with leading drug developers to increase IP potential, identify faster routes to market, and improve patient responses. Sonrai helps you discover and validate new drug candidates, accelerate the drug discovery process and enable the development of personalized medicine. Discover the potential of our AI suite to identify potential therapeutic targets and benefit patients.
Sonrai For AI Drug Development
Our cutting-edge AI tools and expert team propel you forward, help you stay on track, and overcome challenges on your road to innovation. With Sonrai, you can unlock your data's full potential, and discover and validate new drug candidates, helping you develop personalized medicine and identify the patients most likely to benefit from a particular treatment.
No matter where you are on your journey, Sonrai can help. Click the buttons below for more information on how we help accelerate drug development with AI.
We provide a range of services to assist drug developers during the research stage of drug development. Using advanced algorithms and machine learning techniques, Sonrai can integrate multi-omic data from various sources to identify potential drug targets and pathways and help to analyze high-throughput screening data sets to identify drug candidates. We harmonize your CRO data to give you the insight you need to accelerate drug development and improve trial success rates.
Research Phase
Sonrai's AI-driven approach helps drug developers accelerate R&D, reduce costs, and improve the likelihood of success for new drug candidates.
Sonrai's advanced algorithms and machine learning techniques provide a more comprehensive understanding of biological systems by integrating multi-omic data from various sources such as genomics, proteomics, metabolomics, and epigenomics.
We enable large-scale analysis to identify changes and discover novel biomarkers for disease diagnosis, prognosis, and treatment. Our expert team helps to analyze high-throughput screening data sets to identify potential drug candidates, predict efficacy and toxicity, and optimize drug development pipelines.
Research Phase
We help you harmonize and leverage the data collected from CROs and labs to improve efficiency and effectiveness. We process and interrogate new data more effectively and share resources and expertise. This helps to establish a highly efficient bridge between research and development and clinical workflows. Our experts work with you to analyze the data generated from clinical trials to determine the safety and efficacy of a drug candidate.
Our approach ensures that compounds with the highest likelihood of success in clinical trials are selected, thereby accelerating the drug development process and reducing the risk of failures in human trials.
Data Analysis
Experiment Optimization
Real-Time Monitoring
Imagine What You Could Discover
We partner with leading drug developers to increase IP potential, identify faster routes to market, and improve patient responses.Our cutting-edge technology utilizes sophisticated algorithms and advanced machine-learning techniques to analyze cell-line and animal model data. We can help optimize study design and identify suitable drug candidates for preclinical development by identifying patterns and relationships within proteomics, metabolomics, and genomics data.
Preclinical Phase
Our approach ensures that compounds with the highest likelihood of success in clinical trials are selected, thereby accelerating the drug development process and reducing the risk of failures in human trials.
Sonrai’s AI technology helps to identify potential therapeutic targets, evaluate the predictive value of potential biomarkers, and develop more targeted therapies by collecting molecular data to inform precision medicine strategies. We also assist in identifying patient subgroups more likely to benefit from a particular treatment and in developing companion diagnostics. By validating potential biomarkers using large datasets and advanced analytical techniques, we help to identify the most robust and clinically relevant biomarkers to use in clinical trials.
Clinical Phase
Collect molecular data to inform your precision medicine strategy. Our advanced analytical tools can analyze genomic and proteomic data from patient samples to identify potential biomarkers that can be used to predict treatment response or disease progression.
By applying sophisticated analytical tools to this data, we can help you identify patient subgroups more likely to benefit from a particular treatment, optimize trial design, and develop more targeted therapies.
Clinical Phase
Develop and validate robust and relevant biomarkers that comply with regulatory requirements, including FDA, by leveraging our biomarker discovery, assay development and analytical validation expertise. Using advanced machine learning algorithms, Sonrai can analyze large datasets from clinical trials to identify potential biomarkers that can be used as companion diagnostics.
Our sophisticated product development and analytical validation services rigorously test and validate these biomarkers to ensure their robustness and clinical relevance. Sonrai can support you, as bespoke tools can be built and tested taking into account GxP practices, ensuring that the biomarkers meet the quality standards for clinical use.
By partnering with Sonrai, you can have confidence in the accuracy and reliability of your companion diagnostics, leading to more effective treatments and improved patient outcomes. Our AI-driven approach reduces the time and costs associated with clinical development, accelerating the path to market.
Our automated analysis of histological images obtained from patient samples can help you identify tumour grade, stage, and other relevant biomarkers. This information can assist you in understanding the disease better, evaluating the drug's efficacy, and identifying potential responders to the therapy during the clinical testing phase.
We aim for perfection for our clients. We listen to their goals, quickly grasp their challenges, consider the needs of all stakeholders and deliver technical solutions. Below are just some of our client case studies to view.
Molecular Test Algorithm
Challenge
For an accurate and efficient method to estimate the DNA content of tumor tissue used in molecular tests.
How We Helped
Our AI algorithm estimates tumor DNA content in macrodissected tissue for molecular tests by analyzing H&E-stained images. It serves as quality control and aids sample suitability for analysis.
High Content Screening
Challenge
HCS projects typically involve numerous fluorescent images that require image analysis before further analysis.
How We Helped
AI's unsupervised learning algorithms can extract features from images to reveal mechanisms of action and in vitro responses across different experimental conditions, enabling efficient HCS data analysis.
